18F-Floretyrosine Access Program for Glioma Patients
Sponsor: Telix Pharmaceuticals (Innovations) Pty Limited
Expanded Access
Sponsor score: 60
Inactive
ClinicalTrials ID:NCT06743100
This program allows patients with glioma to use a special imaging technique called 18F-Floretyrosine PET/CT or PET/MR to help doctors see the tumor and any changes from treatment, aiding in better management of the condition.
Patient Parameters
| Parameter | Options |
|---|
Program Overview
The purpose of this program is to provide access to a special imaging method using 18F-Floretyrosine with PET/CT or PET/MR scans. This technique helps doctors noninvasively detect the size and changes in brain tumors, known as gliomas, to assist in making the best treatment decisions.
Eligibility Criteria
Inclusion Criteria
- Must provide written consent to participate. For children under 18, both the child and their parent or guardian must agree.
- Must be 3 years or older.
- Must have a diagnosis or suspicion of glioma in the brain.
- Must have already received treatment for glioma.
- Must have unclear MRI results that need further investigation within 60 days before the 18F-Floretyrosine PET scan.
- Must be able to stay still for at least 40 minutes during the scan or be able to undergo sedation if needed.
Exclusion Criteria
- Cannot have any metal or devices in the body that are not safe for MRI, unless the PET/CT scan can be used instead.
- Cannot be pregnant or breastfeeding.
- Women who can become pregnant must use birth control during the program.
- Cannot have serious non-cancerous diseases that might interfere with the program.
- Cannot have mental impairments that affect understanding or following the program.
- Cannot have taken any experimental drugs within 30 days before the scan.
- Cannot be allergic to floretyrosine or similar substances.
- Must be able to handle the program procedures.
Get This Program In Your Inbox
Receive detailed information about this treatment opportunity to review with your healthcare provider.